Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
Список исп. литературыСкрыть список 1. Hughes TA, Ross HF, Mindham RHS et al. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004; 110: 118–23. 2. Cummings JL. Depression in Parkinson’s disease. Am J Psychiatry 1992; 149: 443–54. 3. Смулевич А.Б. Клиника и систематика депрессий у соматически больных. Рус. мед. журн. 1998; 2: 10–5. 4. Troster AI, Fields JA, Koller WC. Parkinson’s disease and Parkinsonism. In: C.E.Coffey, J.L.Cummings (eds). Textbook of Geriatric Neuropsychiatry. 2nd ed. Washington, DC: American Psychiatric Press, 2000; p. 559–600. 5. Oertel WH, Hoglinger GU, Caraceni T et al. Depression in Parkinson’s disease. Adv Neurol 2001; 86: 373–83. 6. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 1998; 49: 341–61. 7. Braak H, Rub U, Braak E. Neuroanatomie des morbus Parkinson. Nervenarzt 2000; 71: 459–69. 8. Becker T, Becker G, Seufert J et al. Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry 1997; 63: 590–6. 9. Lieberman A. Depression in Parkinson’s disease – a review. Acta Neurol Scand 2006; 113: 1–8. 10. Lemke M, Raethjen J. Depression and Parkinson’s disease – pathophysiology, diagnosis, treatment. Bremen: UNI-MED, 2007. 11. Hubble JP, Cao T, Hassanein RE et al. Risk Factors for Parkinson’s disease. Neurology 1993; 43: 1693–7. 12. Slaugher JR, Slaugher KA, Nichols D et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsych Clin Neurosci 2001; 13: 187–96. 13. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Mental Dis 1990; 178: 27–31. 14. Burn DJ. Depression in Parkinson’s disease. Eur J Neurol 2002; 9 (Suppl. 3): 44–54. 15. Marsh L, McDonald WM, Cummings J et al. Provisional diagnostic criteria for depression in Parkinson’s disease; report of an NIDS/NIMN work group. Mov Disord 2006; 21: 148–58. 16. Friedman JH, Chou KL. Sleep and fatigue in Parkinson’s disease. Parkinsonism Relat Disord 2004; 10 (Suppl. 1): 27–35. 17. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 1988; 11: 512–9. 18. Kaynak D, Kiziltan G, Kaynak H et al. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Eur J Neur 2005; 12: 199–207. 19. Marin R. Apathy: a neuropsychiatric syndrome. J Neuropsyh Clin Neurosci 1991; 3: 243–54. 20. Starkstein SE, Leentjens AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008; 79 (10): 1088–92. 21. Czernecki V, Pillon B, Houeto JL et al. Motivation, reward, and Parkinson’s disease: influence of dopa-therapy. Neuropsychology 2002; 40: 2257–67. 22. Remy P et al. Depression in Parkinson’s disease loss of dopamine and adrenaline innervation in the limbic system. Brain 2005; 128: 1314–22. 23. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson’s disease. J Neurol 2001; 248 (Suppl. 3):12–21. 24. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychol 1996; 57: 449–54. 25. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 2001; 50 (Suppl. 3): 1–63. 26. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 1991; 6: 293–303. 27. George MS, Wasserman EM, Post RM. Transcranial magnetic stimulation: a neuropsychiatry tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996; 8: 373–82. 28. Kennedy SH, Rizvi SJ. Agomelatine in the Treatment of Major Depressive Disorder. Potential for Clinical Effectiveness. CNS Drugs 2010; 24 (6): 479–99. 29. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Терапия непсихотических депрессий антидепрессантом агомелатином (Вальдоксан): результаты наблюдательного многоцентрового исследования «РИТМ». Психиатрия и психофармакотерапия. 2010; 12 (4): 4–11. / Smulevich A.B., Andriushchenko A.V., Beskova D.A. Terapiia nepsikhoticheskikh depressii antidepressantom agomelatinom (Val'doksan): rezul'taty nabliudatel'nogo mnogotsentrovogo issledovaniia «RITM». Psychiatry and Psychopharmacotherapy. 2010; 12 (4): 4–11. [in Russian] 30. Иванов С.В. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС»). 2009; 11 (6): 14–7. / Ivanov S.V. Val'doksan (agomelatin) pri terapii umerennykh i tiazhelykh depressii nepsikhoticheskogo urovnia v ambulatornoi i gospital'noi praktike (rezul'taty Rossiiskogo mul'titsentrovogo issledovaniia «KhRONOS»). 2009; 11 (6): 14–7. [in Russian] 31. Ginnantoni D, Loniog D, Cugulierro R et al. Major depressive disorder, anhedonia and agomelatin – an open label study. Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder. A Pilot Study. J Biol Regul Homeost Agents 2011; 25: 109–14. 32. Kasper S, Hajak G, Wulff K et al. Efficacy the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline. J Clin Psychiatry 2010; 71: 109–20. 33. Воробьева О.В. Вальдоксан в терапии депрессии в неврологической практике: результаты российского многоцентрового натуралистического исследования «Резонанс». Журн. неврологии и психиатрии им. С.С.Корсакова. 2012; 9: 47–51. / Vorob'eva O.V. Val'doksan v terapii depressii v nevrologicheskoi praktike: rezul'taty rossiiskogo mnogotsentrovogo naturalisticheskogo issledovaniia «Rezonans». Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 9: 47–51. [in Russian] 34. Hale A, Corral R, Mencacci C et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010. 35. Stein D, Ahokas A, Bodinat C. Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol 2008; 28: 561–66. 36. Goodwin G, Emsle R, Rembry S et al. Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of an annihilation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry 2009; 8 (70): 1128–39. 37. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27–44. 38. Hughes AJ, Ben-Shlomo Y, Daniel SE et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 1992; 42: 1142–6. 39. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17 (5): 427–42. 40. Hamilton M. Development of rating scale, for primary depressive illness. Br J Clin Psychol 1967; 6 (4): 278–96. 41. Teylor J. Tеylor’s Manifest Anxiety Scale and intelligence. J Abnorm Soc Psychol 1953; 51 (2): 347. 42. Snaith R, Hamilton M, Morley S et al. A scale for the assessment of hedonic tone: the Snaith–Hamilton Pleasure Scale. Br J Psyahiatry 1995; 167: 99–103. 43. Sockeel P, Dujardin K, Devos D et al. The little apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 579–84. 44. Buysee DJ, Reynolds CF, Monk TH et al. The Pittsburg sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28 (2): 193–213. 45. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995; 4: 241–8. 46. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Third symposium on Parkinson’s disease. F.G.Gillingham, M.C.Donaldson (eds). Edinburgh, 1969; p. 152–7. 47. Johns MW. Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993; 103: 30–6.